January 31, 2018 / 12:04 PM / in 9 minutes BRIEF-Cara Therapeutics Initiates Pivotal Phase 3 Efficacy Trial Of Korsuva Injection Reuters Staff 1 Min Read 
Jan 31 (Reuters) - Cara Therapeutics Inc: 
* CARA THERAPEUTICS INITIATES PIVOTAL PHASE 3 EFFICACY TRIAL OF KORSUVAâ„¢ (CR845/DIFELIKEFALIN) INJECTION IN HEMODIALYSIS PATIENTS WITH CHRONIC KIDNEY DISEASE-ASSOCIATED PRURITUS Source text for Eikon: Further company coverage: